teva pharmaceuticals stock — Overview

Teva Pharmaceutical Industries Ltd. (TEVA) — Stock

This article explains the teva pharmaceuticals stock in clear, practical terms for beginners and investors. The teva pharmaceuticals stock refers to the U.S.-listed American Depositary Receipt (ADR) of Teva Pharmaceutical Industries Ltd., commonly quoted under the ticker TEVA on the New York Stock Exchange. Readers will learn where TEVA is listed, how to read basic market data, the company background, historic drivers of price movement, key financial metrics to review, major risks and potential catalysts, and where to find verified investor resources. By the end you will know how to locate up-to-date quotes, company filings, and how to trade the ADR using regulated brokerages and Bitget-supported services.

Overview

The teva pharmaceuticals stock is the publicly traded equity representing Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company headquartered in Israel. This article covers the stock’s market listing, identifiers, typical performance drivers, financial measures investors monitor, corporate actions (dividends, splits), major shareholders and insider activity, analyst coverage and sentiment, risks and controversies, and practical trading information. It is designed to be beginner-friendly, citing where to verify facts using primary company resources and leading financial data providers.

As of 2026-01-26, according to Teva Investor Relations and major market quote providers, TEVA is traded as an ADR listed in U.S. dollars on the New York Stock Exchange under the ticker TEVA. For current market capitalization, daily volume and other real-time metrics, consult the company’s investor relations page and live market data pages such as Yahoo Finance, CNBC, and Morningstar.

Company background (brief)

Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company founded in the early 20th century and headquartered in Israel. The company is known for a large portfolio of generic medicines, a presence in specialty pharmaceuticals (including treatments for multiple sclerosis and other central nervous system conditions), and efforts in biosimilars and novel drug development. Teva’s business model historically combined scale in generics with targeted investment in branded specialty drugs. Over time, the company has faced industry-wide generics pricing pressure while managing legacy liabilities, restructuring and refocusing R&D to support specialty and biosimilar offerings.

Understanding the teva pharmaceuticals stock requires context about this business mix: generics drive volume and recurring revenue but have lower margins; specialty drugs can command higher margins but require successful R&D and regulatory approvals. Corporate actions, patent expirations, and legal outcomes have been recurring drivers of the equity’s price.

Listing and ticker information

Primary exchange and ticker

The teva pharmaceuticals stock is listed on the New York Stock Exchange (NYSE) as an American Depositary Receipt (ADR) under the ticker symbol TEVA. The ADR provides U.S.-domiciled investors with an accessible means to trade shares representing ownership in the underlying foreign company.

Teva may also maintain listing(s) in other jurisdictions, including its home market (e.g., local exchange listings), but the NYSE ADR is the primary U.S. trading vehicle most international investors reference when discussing TEVA.

Securities identifiers

Important identifiers for the teva pharmaceuticals stock include the ticker (TEVA), the ADR designation used by brokers, and issuer identifiers such as ISIN and CUSIP for the ADR series. These identifiers are listed on the company investor relations pages and on major market quote services. An ADR represents a specified number of underlying ordinary shares held by a depositary bank; the ADR simplifies cross-border trading and dividend handling for U.S. investors.

Trading hours and currency

The teva pharmaceuticals stock trades on the NYSE during U.S. market hours and is quoted in U.S. dollars (USD). Regular NYSE trading hours are the primary session used by most market participants; pre-market and after-hours trading are also available through many broker platforms but may have different liquidity and price behavior. When comparing to local listings, note currency conversion and differing trading hours.

Historical stock performance

Price history and major trends

The teva pharmaceuticals stock has experienced multi-year volatility tied to company-specific and industry-wide factors. Periods of strong performance often aligned with positive regulatory approvals, successful product launches in specialty areas, or effective cost and portfolio restructuring. Conversely, notable declines have occurred after patent expirations for key products, generics pricing pressure, unexpected earnings misses, or large legal settlements.

Long-term investors typically observe cycles related to the pharmaceutical lifecycle: patent-protected products provide periods of higher profitability, followed by generics competition that compresses revenue and margins. Teva’s strategic shift and restructuring efforts in recent years have aimed to stabilize cash flow and reduce debt, which also influenced share price trends.

Notable historical events affecting the stock

Significant corporate milestones and external events have materially affected TEVA share performance in the past, including:

• Major acquisitions that altered the company’s debt profile and strategic focus.
• Patent expirations and the so-called “patent cliff” for certain branded products.
• Litigation outcomes, settlements or regulatory fines that created one-time charges or future liabilities.
• Product approvals or trial results in specialty pipelines that either uplifted or lowered investor expectations.

For precise dates and detailed event summaries, consult the company’s press releases and the investor relations timeline; these are primary sources for event descriptions and any quantitative disclosures tied to those events.

Financial metrics and recent results

Key financial indicators

Investors reviewing the teva pharmaceuticals stock typically monitor the following quantitative metrics:

• Market capitalization (total equity market value).
• Revenue and revenue growth trends (quarterly and annual).
• Earnings per share (EPS) and adjusted EPS, which exclude certain one-time or non-cash items.
• Price-to-earnings ratio (P/E) for relative valuation.
• Enterprise value and EV/EBITDA for capital structure-aware valuation.
• Gross margin and operating margin to assess profitability.
• Net debt and debt-to-EBITDA ratios to evaluate leverage and solvency.
• Free cash flow and operating cash flow for liquidity and ability to invest or reduce debt.

These figures appear in the company’s quarterly (10-Q) and annual (10-K or equivalent) reports, and on major market data pages such as Yahoo Finance, Morningstar and CNBC. As of 2026-01-26, investors should check the most recent quarterly filing for exact values and management commentary.

Recent earnings and guidance

Quarterly earnings reports and management guidance can cause meaningful stock moves for the teva pharmaceuticals stock. Investors commonly look at reported revenue vs. consensus estimates, adjusted EPS outcomes, and any forward guidance revisions. Management presentations and analyst Q&A transcripts included with earnings releases provide context on expectations for product launches, cost savings, and debt reduction plans.

When reviewing recent results, prioritize the issuer’s official press release and the investor presentation for the quarter; these include reconciliations of non-GAAP measures and discussion of one-time items.

Dividends, splits and corporate actions

Dividend policy and history

Teva’s dividend policy has varied over time depending on cash flow, leverage and strategic priorities. Some periods featured dividend payments while others emphasized debt reduction or reinvestment in the business. Investors seeking yield should confirm the company’s latest dividend declaration on the investor relations page and review the dividend history reported by financial data providers.

Dividend yield and payout consistency are part of the total return assessment for the teva pharmaceuticals stock; changes to dividend policy can influence investor sentiment and valuation.

Stock splits and share capital changes

Share capital decisions—such as stock splits, reverse splits, share buybacks, or issuances—change the outstanding shares and can affect liquidity and earnings per share. Teva has executed corporate actions historically; any recent or planned changes to share capital will be disclosed in regulatory filings and press releases. For accuracy, verify split ratios, record dates and intended purposes through the official company announcements.

Major shareholders and insider activity

Institutional investors (asset managers, pension funds, and mutual funds) typically own a large portion of public pharmaceutical companies, and the teva pharmaceuticals stock is no exception. Regulatory filings—such as 13F filings by institutional managers and Form 4 submissions for insider transactions—are public records in the U.S. market and provide insights into changes in large holdings and insider purchases or sales.

Monitoring significant increases or decreases in institutional stakes and insider activity helps investors understand confidence levels among informed parties. Major ownership concentrations can also affect float and volatility; these details appear on the company’s filings and in major market-data pages.

Analyst coverage and market sentiment

Analyst ratings and price targets

Brokerage and independent equity analysts publish research notes that include ratings (buy/hold/sell) and price targets. For the teva pharmaceuticals stock, analyst coverage is commonly available from independent research platforms and financial news organizations. Analyst revisions and upgraded or downgraded ratings can create short-term price moves, although analysts’ views should be considered alongside fundamental company data and regulatory disclosures.

Investor sentiment and news flow

Short-term sentiment for teva pharmaceuticals stock often reacts to news flow: regulatory decisions, trial outcomes, earnings surprises, supply issues, or macro-level drug-pricing policy changes. Trading volume spikes usually accompany significant news events, and social/retail investor attention can amplify intraday volatility. Reliable news sources and the company’s press releases are primary references to evaluate sentiment drivers.

Risks and controversies

Industry and company-specific risks

Pharmaceutical companies face a set of industry-wide risks that also apply to Teva and the teva pharmaceuticals stock:

• Regulatory risk: failure to obtain approvals or unexpected regulatory conditions can delay or block product launches.
• Pricing and reimbursement risk: generic pricing competition and changes in government or insurer reimbursement can reduce revenue.
• Patent and IP risk: expiration of patents or successful challenges to exclusivity reduce protected revenue streams.
• Competition: other generics manufacturers, biosimilars, and branded drugmakers can erode market share.
• Manufacturing and supply chain risk: disruptions or quality issues can affect product availability and reputation.

Company-specific risks include legacy litigation, high leverage from past acquisitions, or strategic execution challenges such as integrating acquired businesses and sustaining R&D productivity.

Regulatory, legal and safety issues

Teva and peers have faced litigation related to product liability, alleged marketing practices, or opioid-related claims in various jurisdictions. Such legal matters may result in settlements or judgments that influence the company’s financial position and the teva pharmaceuticals stock price. Regulatory inspections, recalls or safety alerts for specific medicines can also lead to volatility; these items are reported in regulatory filings and in company press releases when material.

For a complete assessment of legal and regulatory exposure, review the company’s risk disclosures in its annual report and recent filings.

Investment considerations

Important: this section is informational and not investment advice. Readers should perform their own due diligence or consult a licensed advisor.

Investment thesis elements

Common arguments investors consider when forming an investment view on the teva pharmaceuticals stock include:

Bull-ish elements:

• Scale and global footprint in generics, providing recurring revenue and manufacturing expertise.
• Specialty portfolio and pipeline that can deliver higher-margin growth if approvals and commercialization succeed.
• Cost-savings and restructuring programs intended to improve margins and cash flow.
• Potential for debt reduction to strengthen balance-sheet metrics.

Bear-ish elements:

• Continued generics pricing pressure and margin compression in commoditized markets.
• Legacy liabilities or sizable legal/settlement risks.
• High leverage limiting financial flexibility.
• R&D and regulatory execution risk for specialty drugs.

Valuation and comparables

Investors typically use multiple valuation approaches when assessing the teva pharmaceuticals stock:

• Relative valuation: compare P/E, EV/EBITDA and P/S to peers in generics and specialty pharmaceuticals.
• Discounted cash flow (DCF): model future free cash flow and discount to present value using an appropriate cost of capital.
• Sum-of-the-parts: evaluate generics and specialty divisions separately and aggregate.

When benchmarking, select peers that represent similar business mixes (large generics manufacturers or diversified pharmas with biosimilars and specialty drugs) and use up-to-date financials from company filings.

How to trade and where to get market data

Trading platforms and order types

To trade the teva pharmaceuticals stock, investors use a regulated brokerage account that supports NYSE trading. Order types commonly used include market orders, limit orders, stop orders and stop-limit orders. International investors should consider ADR availability in their jurisdiction and possible tax implications.

For traders who use integrated services, Bitget provides trading tools and market access for equities and other asset classes where available; when using any platform, verify supported instruments and account requirements before placing trades. Bitget Wallet is a recommended option in this document when discussing custody for crypto assets or Web3 interactions, but for equities, custody and settlement will depend on the brokerage used.

Reliable data sources

Primary sources for reliable, up-to-date market data on the teva pharmaceuticals stock include:

• The company’s Investor Relations site for press releases, earnings materials, and filings.
• Regulatory filings for audited financials and detailed risk disclosures.
• Reputable market-data providers for real-time quotes and historical charts.

As of 2026-01-26, consult the company IR page and major financial news platforms for live market cap, daily trading volume, and analyst coverage. These sources are the basis for verifying quantitative metrics cited in summaries.

Investor relations and filings

Official company communications are the authoritative source for material information about Teva and the teva pharmaceuticals stock. Key investor resources include:

• Quarterly and annual reports (including audited financial statements and MD&A).
• Current reports and material event filings.
• Earnings press releases and investor presentation decks.
• Webcasts and transcripts of earnings calls and investor days.

Investors should monitor these primary documents for precise numeric disclosures and management commentary; compare them with independent data providers when assessing market prices and ratios.

Recent news and catalysts

Near-term catalysts that commonly move the teva pharmaceuticals stock include:

• Quarterly earnings announcements and management guidance updates.
• Regulatory approvals or negative rulings for pipeline assets.
• Clinical trial data readouts for specialty or biosimilar candidates.
• Major corporate restructurings, divestitures, or strategic partnerships.
• Material legal outcomes or settlements.

As of 2026-01-26, investors are advised to follow the company’s press release feed and verified financial news outlets to capture these events in real time. For each event, confirm the original company disclosure date and source when measuring impact on the stock.

See also

• Pharmaceutical industry overview
• Generic drug market dynamics
• American Depositary Receipts (ADRs) explained
• Comparable companies in generics and specialty pharma

References and external guidance

For up-to-date, authoritative information about the teva pharmaceuticals stock, consult the following primary sources and trusted financial data providers. Always verify the publication date of each item cited.

• Teva Investor Relations and company press releases for official disclosures and filings. (As of 2026-01-26, check the investor relations site for the latest reports and presentations.)
• Major market-data providers’ TEVA quote pages for live price, market capitalization and volume.
• Professional research notes and consensus data from independent analysts; verify the reporting date and the data vendor.

As of 2026-01-26, according to standard market data platforms and the company IR, TEVA remains listed on the NYSE as an ADR under ticker TEVA. For real-time market capitalization and average daily volume, consult those pages directly; quotes and volumes update intraday and should be checked at the moment of trading.

Practical next steps for readers

• Verify the latest market data for the teva pharmaceuticals stock on the company investor relations page and a live market quote provider at the time you plan to act.
• Read the most recent quarterly filing and earnings presentation to understand current revenue trends, margin drivers and management guidance.
• Monitor material legal disclosures and major clinical or regulatory announcements that could affect near-term price movement.
• If you intend to trade, open an account with a regulated brokerage that supports NYSE ADR trading; for traders using integrated services, explore Bitget’s platform features and Bitget Wallet for Web3 custody where applicable.

Further exploration: review peer company filings and independent analyst reports to build a comparative perspective and ensure any investment decision is supported by diverse primary sources.

Note: This article is informational and neutral in tone. It is not investment advice. For precise, dated numeric figures (market cap, daily volume, price, outstanding shares), consult the company investor relations pages and live market data providers cited above. As of 2026-01-26, authoritative disclosure sources include the company’s investor relations and filings, and leading market-data platforms.